Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.

× No keyword cloud information.

26 in total

1. Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.

Authors: Omprakash Tanwar; Girdhar Singh Deora; Lalima Tanwar; Gautam Kumar; Sridhara Janardhan; Mumtaz Alam; Mymoona Akhter
Journal: J Mol Model Date: 2014-04-01 Impact factor: 1.810

Review 2. Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?

Authors: Lin Li
Journal: Neurosci Bull Date: 2007-01 Impact factor: 5.203

Review 3. Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors: Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal: Pharmacol Rev Date: 2016-10 Impact factor: 25.468

Review 4. Revisiting amino acids and peptides as anti-glycation agents.

Authors: H Chilukuri; M J Kulkarni; M Fernandes
Journal: Medchemcomm Date: 2018-02-12 Impact factor: 3.597

5. Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control.

Authors: Miriam Amiram; Kelli M Luginbuhl; Xinghai Li; Mark N Feinglos; Ashutosh Chilkoti
Journal: Proc Natl Acad Sci U S A Date: 2013-01-28 Impact factor: 11.205

6. Effects of nitric oxide synthase inhibition with or without cyclooxygenase-2 inhibition on resting haemodynamics and responses to exendin-4.

Authors: S M Gardiner; J E March; P A Kemp; T Bennett
Journal: Br J Pharmacol Date: 2006-10-03 Impact factor: 8.739

7. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.

Authors: M Shimoda; Y Kanda; S Hamamoto; K Tawaramoto; M Hashiramoto; M Matsuki; K Kaku
Journal: Diabetologia Date: 2011-02-22 Impact factor: 10.122

Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.